Last updated: February 13, 2026
What is NDC 70677-1079?
NDC 70677-1079 refers to Mavenclad (cladribine), a drug approved for the treatment of relapsing forms of multiple sclerosis (MS). It is marketed by Merck KGaA. Mavenclad is an oral, short-course therapy that offers a distinct treatment regimen compared to older MS therapies.
Market Overview
Indications and Usage
- Relapsing MS: Used to reduce relapses
- Active secondary progressive MS: Approved based on clinical trials
- Treatment schedule: Administered as two annual courses (one each year), with an initial two-week treatment cycle, followed by a second cycle twelve months later, with no continuous therapy needed
Market Size and Growth Drivers
- The MS therapeutics market was valued at approximately $24.8 billion globally in 2022 (source: IQVIA)
- The MS market is expected to grow at a compound annual growth rate (CAGR) of 4% from 2023 to 2030
- Mavenclad's share within oral MS therapies is increasing, capturing prescriptions from competitors like Tecfidera (dimethyl fumarate), Aubagio (teriflunomide), and Gilenya (fingolimod)
- Growing awareness for patient-friendly, short-course treatments enhances Mavenclad’s competitive advantage
Key Competitive Landscape
- Primary competitors: Tecfidera, Aubagio, Gilenya
- Other DMTs: Ocrevus (ocrelizumab), Kesimpta (ofatumumab)
- Mavenclad's oral, pulse-dosing regimen positions it favorably among patients preferring less frequent dosing
Market Penetration and Reimbursement Landscape
- FDA approval since 2019 (original approval) with expanded label in 2021 for active secondary progressive MS
- CE mark and other regulatory clearances in Europe, Canada, and Australia
- Reimbursement policies are increasingly favorable; coverage varies by country but generally includes MS treatment plans under multiple health systems
- Hospital prescribing remains a core segment, with increasing outpatient adoption
Price Trends and Projections
Current Pricing
- U.S. Average Wholesale Price (AWP): Roughly $7,000 per 28-day treatment cycle (per literature, [1])
- The total annual cost per patient: approximately $70,000, considering two treatment courses per year
- In Europe, the price varies between €40,000 and €58,000 annually, depending on country and reimbursement agreements
Historical Price Changes
- Estimated initial launch price (2019): $7,000 per cycle
- No significant inflation-adjusted price hikes observed through 2022
- Price stability attributable to competitive dynamics and rebate arrangements
Forecast for Future Prices (2023-2027)
- Short-term: Prices are expected to remain stable in the U.S. and Europe, assuming no patent or regulatory changes
- Medium-term: No significant price reductions forecasted unless patent expirations or biosimilar entries occur
- Potential downward pressure if biosimilar or generic alternatives emerge, though current data suggests biologic me-too entrants remain years away
Regulatory and Policy Impact
- Patent status: Merck KGaA holds patents expected to last through 2025-2026 in key markets
- Patent cliffs: Not imminent; biosimilar competition unlikely in the short term due to the nature of the product
- Pricing and access reforms: Trends towards managed access and value-based pricing could influence future price points
Market Risks
- Competitive erosion: Entry of new oral DMTs
- Regulatory changes: Stringent cost controls or new approval requirements
- Reimbursement limitations: Variability across markets affecting net prices and market share
Summary
| Parameter |
Value/Projection |
| Current price (U.S.) |
~$7,000 per cycle |
| Estimated annual cost |
~$70,000 per patient |
| Market size (2022) |
$24.8 billion globally |
| Growth rate (2023-2030) |
4% CAGR |
| Price stability outlook |
Stable over next 2 years, minimal reduction expected until patent expiration |
Key Takeaways
- Mavenclad's pricing remains stable, with an annual cost of approximately $70,000 per patient.
- The drug benefits from increasing market penetration due to its efficacy profile and convenient dosing.
- Competitive pressures from oral and infusion MS therapies could influence future pricing but are unlikely to cause steep declines in the short term.
- Patent protections delay biosimilar or generic entry until 2025-2026 in key markets.
- Policy shifts toward value-based pricing could alter pricing dynamics in the next 5 years.
FAQs
Q1. Will Mavenclad prices decline significantly after patent expiry?
A1. Likely; biosimilar or generic entrants could reduce prices by 20%-50%, assuming market adoption.
Q2. Are there upcoming regulatory decisions that may impact Mavenclad's market?
A2. No major approvals or patent expirations are imminent before 2025. Future label expansions or new indications could impact demand.
Q3. How does Mavenclad’s price compare with other MS therapies?
A3. It is comparable to other oral DMTs; for example, Tecfidera costs about $72,000 annually, with variations across regions.
Q4. What impact could policy reforms have on Mavenclad's market?
A4. Price controls, value-based payment models, or cost-effectiveness assessments could pressure prices downwards.
Q5. Is there potential for market expansion in emerging markets?
A5. Yes, especially where MS diagnosis and treatment infrastructure grow; however, pricing strategies will depend on local reimbursement policies.
Sources
[1] IQVIA. "Global MS Therapeutics Market Report," 2022.
